BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 35577029)

  • 1. Hepatoblastomas with carcinoma features represent a biological spectrum of aggressive neoplasms in children and young adults.
    Sumazin P; Peters TL; Sarabia SF; Kim HR; Urbicain M; Hollingsworth EF; Alvarez KR; Perez CR; Pozza A; Najaf Panah MJ; Epps JL; Scorsone K; Zorman B; Katzenstein H; O'Neill AF; Meyers R; Tiao G; Geller J; Ranganathan S; Rangaswami AA; Woodfield SE; Goss JA; Vasudevan SA; Heczey A; Roy A; Fisher KE; Alaggio R; Patel KR; Finegold MJ; López-Terrada DH
    J Hepatol; 2022 Oct; 77(4):1026-1037. PubMed ID: 35577029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Profiling of a Hepatocellular Neoplasm Not Otherwise Specified (HCN-NOS) Demonstrates Distinct Molecular Features in Hepatoblastoma and HCC-Like Components.
    Chen Wongworawat Y; Sarabia SF; Urbicain M; Francalanci P; Sumazin P; Alaggio R; López-Terrada DH
    Pediatr Dev Pathol; 2024; 27(2):169-175. PubMed ID: 37903123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatoblastoma and Pediatric Hepatocellular Carcinoma: An Update.
    Ranganathan S; Lopez-Terrada D; Alaggio R
    Pediatr Dev Pathol; 2020; 23(2):79-95. PubMed ID: 31554479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Clinicopathologic and Genomic Analysis of Hepatocellular Neoplasm, Not Otherwise Specified, and Hepatoblastoma.
    Zhou S; Sarabia SF; Estrine D; Ostrow D; Schmidt RJ; Warren M; Raca G; Shillingford N; Wang L; Pawel B; Stein JE; Biegel JA; Lopez-Terrada D; Mascarenhas L; Ji J
    Mod Pathol; 2024 Feb; 37(2):100385. PubMed ID: 37992967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histologic type predicts disparate outcomes in pediatric hepatocellular neoplasms: A Pediatric Surgical Oncology Research Collaborative study.
    Short SS; Kastenberg ZJ; Wei G; Bondoc A; Dasgupta R; Tiao GM; Watters E; Heaton TE; Lotakis D; La Quaglia MP; Murphy AJ; Davidoff AM; Mansfield SA; Langham MR; Lautz TB; Superina RA; Ott KC; Malek MM; Morgan KM; Kim ES; Zamora A; Lascano D; Roach J; Murphy JT; Rothstein DH; Vasudevan SA; Whitlock R; Lal DR; Hallis B; Bütter A; Baertschiger RM; Lapidus-Krol E; Putra J; Tracy ER; Aldrink JH; Apfeld J; Le HD; Park KY; Rich BS; Glick RD; Fialkowski EA; Utria AF; Meyers RL; Riehle KJ
    Cancer; 2022 Jul; 128(14):2786-2795. PubMed ID: 35561331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications.
    Carrillo-Reixach J; Torrens L; Simon-Coma M; Royo L; Domingo-Sàbat M; Abril-Fornaguera J; Akers N; Sala M; Ragull S; Arnal M; Villalmanzo N; Cairo S; Villanueva A; Kappler R; Garrido M; Guerra L; Sábado C; Guillén G; Mallo M; Piñeyro D; Vázquez-Vitali M; Kuchuk O; Mateos ME; Ramírez G; Santamaría ML; Mozo Y; Soriano A; Grotzer M; Branchereau S; de Andoin NG; López-Ibor B; López-Almaraz R; Salinas JA; Torres B; Hernández F; Uriz JJ; Fabre M; Blanco J; Paris C; Bajčiová V; Laureys G; Masnou H; Clos A; Belendez C; Guettier C; Sumoy L; Planas R; Jordà M; Nonell L; Czauderna P; Morland B; Sia D; Losic B; Buendia MA; Sarrias MR; Llovet JM; Armengol C
    J Hepatol; 2020 Aug; 73(2):328-341. PubMed ID: 32240714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The genomic landscape of hepatoblastoma and their progenies with HCC-like features.
    Eichenmüller M; Trippel F; Kreuder M; Beck A; Schwarzmayr T; Häberle B; Cairo S; Leuschner I; von Schweinitz D; Strom TM; Kappler R
    J Hepatol; 2014 Dec; 61(6):1312-20. PubMed ID: 25135868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantification of glypican 3, β-catenin and claudin-1 protein expression in hepatoblastoma and paediatric hepatocellular carcinoma by colour deconvolution.
    Zhou S; Parham DM; Yung E; Pattengale P; Wang L
    Histopathology; 2015 Dec; 67(6):905-13. PubMed ID: 25939253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Copy Number Alterations in Hepatoblastoma: Literature Review and a Brazilian Cohort Analysis Highlight New Biological Pathways.
    Barros JS; Aguiar TFM; Costa SS; Rivas MP; Cypriano M; Toledo SRC; Novak EM; Odone V; Cristofani LM; Carraro DM; Werneck da Cunha I; Costa CML; Vianna-Morgante AM; Rosenberg C; Krepischi ACV
    Front Oncol; 2021; 11():741526. PubMed ID: 34956867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful treatment of a metastatic hepatocellular malignant neoplasm, not otherwise specified with chemotherapy and liver transplantation.
    Seng MS; Berry B; Karpelowsky J; Thomas G; Mews C; Stormon M; Shun A; Cole C
    Pediatr Blood Cancer; 2019 Apr; 66(4):e27603. PubMed ID: 30609257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatocellular malignant neoplasm, NOS: a clinicopathological study of 11 cases from a single institution.
    Zhou S; Venkatramani R; Gupta S; Wang K; Stein JE; Wang L; Mascarenhas L
    Histopathology; 2017 Nov; 71(5):813-822. PubMed ID: 28660626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic alterations in hepatoblastoma and hepatocellular carcinoma: common and distinctive aspects.
    Buendia MA
    Med Pediatr Oncol; 2002 Nov; 39(5):530-5. PubMed ID: 12228912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity.
    Moeini A; Sia D; Zhang Z; Camprecios G; Stueck A; Dong H; Montal R; Torrens L; Martinez-Quetglas I; Fiel MI; Hao K; Villanueva A; Thung SN; Schwartz ME; Llovet JM
    J Hepatol; 2017 May; 66(5):952-961. PubMed ID: 28126467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of pediatric hepatocellular carcinoma reveals genomic heterogeneity and diverse signaling pathway activation.
    Haines K; Sarabia SF; Alvarez KR; Tomlinson G; Vasudevan SA; Heczey AA; Roy A; Finegold MJ; Parsons DW; Plon SE; López-Terrada D
    Pediatr Blood Cancer; 2019 Jul; 66(7):e27745. PubMed ID: 30977242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of genomic alterations in hepatoblastomas. A role for gains on chromosomes 8q and 20 as predictors of poor outcome.
    Weber RG; Pietsch T; von Schweinitz D; Lichter P
    Am J Pathol; 2000 Aug; 157(2):571-8. PubMed ID: 10934159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas.
    Taniguchi K; Roberts LR; Aderca IN; Dong X; Qian C; Murphy LM; Nagorney DM; Burgart LJ; Roche PC; Smith DI; Ross JA; Liu W
    Oncogene; 2002 Jul; 21(31):4863-71. PubMed ID: 12101426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pediatric Liver Tumors: Updates in Classification.
    Cho SJ
    Surg Pathol Clin; 2020 Dec; 13(4):601-623. PubMed ID: 33183723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Downregulation of SFRP1 is a protumorigenic event in hepatoblastoma and correlates with beta-catenin mutations.
    Regel I; Eichenmüller M; Mahajan UM; Hagl B; Benitz S; Häberle B; Vokuhl C; von Schweinitz D; Kappler R
    J Cancer Res Clin Oncol; 2020 May; 146(5):1153-1167. PubMed ID: 32189106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and experimental validation of druggable epigenetic targets in hepatoblastoma.
    Clavería-Cabello A; Herranz JM; Latasa MU; Arechederra M; Uriarte I; Pineda-Lucena A; Prosper F; Berraondo P; Alonso C; Sangro B; García Marin JJ; Martinez-Chantar ML; Ciordia S; Corrales FJ; Francalanci P; Alaggio R; Zucman-Rossi J; Indersie E; Cairo S; Domingo-Sàbat M; Zanatto L; Sancho-Bru P; Armengol C; Berasain C; Fernandez-Barrena MG; Avila MA
    J Hepatol; 2023 Oct; 79(4):989-1005. PubMed ID: 37302584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. State of the art and perspectives in pediatric hepatocellular carcinoma.
    Digiacomo G; Serra RP; Turrini E; Tiri A; Cavazzoni A; Alfieri R; Bertolini P
    Biochem Pharmacol; 2023 Jan; 207():115373. PubMed ID: 36513143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.